Drug intelligence / Profile preview

calcium lysinate + cholecalciferol

Development stage
Unknown
Lead developer
Puneet Laboratories
Modality
Small Molecules
Administration
Oral
01

Overview

Calybest is an oral fixed-dose combination supplement developed by Puneet Laboratories, containing 250 mg of calcium lysinate and 500 IU of vitamin D3 (cholecalciferol). Calcium lysinate is a chelated form of calcium where the mineral is bound to the amino acid L-lysine, a formulation intended to improve gastrointestinal absorption and reduce common side effects associated with inorganic calcium salts. Vitamin D3 acts as a crucial regulator of calcium and phosphate homeostasis by binding to the vitamin D receptor (VDR), thereby enhancing intestinal calcium absorption and promoting bone mineralization. This combination is primarily indicated for the prevention and treatment of bone-related conditions such as osteopenia, osteoporosis, and postmenopausal osteoporosis, as well as for meeting increased nutritional demands during pregnancy and lactation and supporting recovery from bone fractures.

Brand names
Calybest
Other names
Calcium Lysinate 250mg & Vitamin D3 500 IUCalcium Lysinate + Vitamin D3
02

Targets

VDR (Vitamin D receptor)

Beyond the preview

Go deeper on calcium lysinate + cholecalciferol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on calcium lysinate + cholecalciferol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call